Per-oral interstitial brachytherapy catheter insertion for boost in case of recurrent tonsillar carcinoma: dosimetry and clinical outcome.
Naoya MurakamiSeiichi YoshimotoSatoshi NakamuraMasakazu UematsuTairo KashiharaKana TakahashiKoji InabaKae OkumaHiroshi IgakiYuko NakayamaJun ItamiPublished in: BJR case reports (2020)
High-dose-rate interstitial brachytherapy (HDR-ISBT) is relatively rarely applied for the head and neck cancer. However, its dose distribution is more confined than intensity modulated radiation therapy (IMRT) and can deliver higher dose while sparing surrounding normal tissues. In this case report, the effectiveness of HDR-ISBT as a boost following IMRT for post-operative recurrent oropharyngeal cancer patient was indicated. A 73-year-old male who developed local recurrence after surgery for oropharyngeal squamous cell carcinoma. Salvage IMRT up to 70 Gy concurrent with weekly cetuximab was planned. However, CT taken at 60 Gy found a residual tumor, then, boost HDR-ISBT was proposed. 1 week after 60 Gy of IMRT, HDR-ISBT, 12 Gy in 2 fractions, was delivered under local anesthesia. MRI taken 2 months after HDR-ISBT showed no residual tumor. It was demonstrated that boost HDR-ISBT following IMRT for local recurrence of oropharyngeal cancer was performed safely and showed favorable efficacy.
Keyphrases
- high dose
- radiation therapy
- locally advanced
- case report
- squamous cell carcinoma
- papillary thyroid
- stem cell transplantation
- low dose
- contrast enhanced
- magnetic resonance imaging
- computed tomography
- squamous cell
- lymph node metastasis
- rectal cancer
- radiation induced
- robot assisted
- clinical trial
- metastatic colorectal cancer
- study protocol
- ultrasound guided
- dual energy
- wild type